Are the levels of Advanced Glycation Endproducts (AGEs) associated with Paratonia in Alzheimers Disease (AD)?

Are the levels of Advanced Glycation Endproducts (AGE*s) associated with Paratonia in Alzheimer*s Disease (AD)? - PARAGE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38761

Enrollment

165

Registered

2013-12-06

Start date

2013-12-10

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paratonia/ Movement stiffness

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Community dwelling patients with Alzheimer's Disease (AD) , with an established diagnosis according to the NINCDS-ARDRA criteria visiting day-care facilities. - Able to walk 10 meters unassisted (walking aid is allowed) - A GDS Reisberg score of 2,3,4 or 5 (the GDS Reisberg is a 7-point scale indicating the severity of cognitive and functional decline in Alzheimer*s disease, from 1= No subjective complaints of memory deficits to 7= Basic psychomotor skills and verbal ability are lost and require assistance in toileting and feeding) - Having a plain colored skin (Caucasian)(due to the limitations of the AGE-reader device)

Exclusion criteria

Exclusion criteria: - Established diagnosis of dementia type other than AD or mixed forms like AD and vascular dementia or AD and Parkinson*s disease - Using psychotropic drugs, as these drugs can possibly mimic paratonic rigidity.

Design outcomes

Primary

Measure	Time frame
1) The presence of paratonia will be assessed with the Paratonia Assessment Instrument (PAI) 2) The severity of present paratonia, assessed with the Modified Ashworth Scale (MAS) Explanatory endpoint) the skin tissue levels of Advanced Glycation Endproducts (N*-CML & Pentosidine), determined by skin autofluorescence (AGE-reader).	—

Secondary

Measure	Time frame
1) The patients functional mobility, assessed with the Timed Up and Go (TUG) 2) Quality of life will be assessed with the QoL-AD 3) Activities of Daily living (ADL) assessed with the Groningen Activity Restriction Scale (GARS) and the Barthel Index 4) Daily activity level will be assessed with the pedometer Patients characteristics at baseline: Gender, age, date of dementia diagnosis, comorbidity (chart diagnosis, including the presence of diabetes mellitus) and the use of medication, global deterioration stage (GDS) [Reisberg 1982] and Mini Mental State Examination (MMSE) [Folstein 1975].	—

Measure

Time frame

1) The patient*s functional mobility, assessed with the Timed Up and Go (TUG) 2) Quality of life will be assessed with the QoL-AD 3) Activities of Daily living (ADL) assessed with the Groningen Activity Restriction Scale (GARS) and the Barthel Index 4) Daily activity level will be assessed with the pedometer Patients* characteristics at baseline: Gender, age, date of dementia diagnosis, comorbidity (chart diagnosis, including the presence of diabetes mellitus) and the use of medication, global deterioration stage (GDS) [Reisberg 1982] and Mini Mental State Examination (MMSE) [Folstein 1975].

—

Countries

Netherlands

Outcome results